# Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

> **NCT02611908** · PHASE1 · WITHDRAWN · sponsor: **Michael Choi**

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** ibrutinib
- **DRUG:** obinutuzumab

## Key facts

- **NCT ID:** NCT02611908
- **Lead sponsor:** Michael Choi
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-06
- **Primary completion:** 2019-11
- **Final completion:** 2020-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants enrolled
- **Last updated:** 2019-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611908, "Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02611908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*